AtriCure (NASDAQ:ATRC) Posts Quarterly Earnings Results

Posted by Francis Steltz on Jul 23rd, 2026

AtriCure (NASDAQ:ATRC – Get Free Report) announced its earnings results on Thursday. The medical device company reported $0.18 earnings per share for the quarter, FiscalAI reports. The firm had revenue of $153.60 million for the quarter, compared to the consensus estimate of $151.80 million. AtriCure had a positive return on equity of 0.29% and a negative net margin of 0.83%. AtriCure updated its FY 2026 guidance to 0.240-0.320 EPS.

AtriCure Stock Performance

Shares of AtriCure stock traded down $0.52 on Thursday, reaching $33.00. The stock had a trading volume of 1,130,682 shares, compared to its average volume of 782,200. AtriCure has a fifty-two week low of $25.36 and a fifty-two week high of $43.18. The stock has a market cap of $1.67 billion, a P/E ratio of -330.00 and a beta of 1.24. The business’s 50-day moving average price is $29.81 and its two-hundred day moving average price is $31.44. The company has a debt-to-equity ratio of 0.15, a quick ratio of 3.18 and a current ratio of 4.29.

Insider Activity

In other news, Director Karen Prange sold 3,000 shares of the firm’s stock in a transaction on Wednesday, May 20th. The shares were sold at an average price of $28.65, for a total value of $85,950.00. Following the sale, the director owned 26,373 shares in the company, valued at approximately $755,586.45. This trade represents a 10.21% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders own 4.00% of the company’s stock.

Institutional Trading of AtriCure

Hedge funds and other institutional investors have recently bought and sold shares of the stock. AQR Capital Management LLC raised its position in shares of AtriCure by 1.0% during the first quarter. AQR Capital Management LLC now owns 83,685 shares of the medical device company’s stock valued at $2,700,000 after buying an additional 837 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in AtriCure by 4.6% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 28,146 shares of the medical device company’s stock valued at $908,000 after acquiring an additional 1,230 shares in the last quarter. Goldman Sachs Group Inc. lifted its position in shares of AtriCure by 1.0% in the 1st quarter. Goldman Sachs Group Inc. now owns 862,668 shares of the medical device company’s stock worth $27,830,000 after acquiring an additional 8,956 shares during the period. Jane Street Group LLC lifted its position in shares of AtriCure by 658.3% in the 1st quarter. Jane Street Group LLC now owns 100,853 shares of the medical device company’s stock worth $3,254,000 after acquiring an additional 87,553 shares during the period. Finally, Strs Ohio acquired a new stake in shares of AtriCure during the 1st quarter worth approximately $158,000. 99.11% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of analysts have commented on the stock. Raymond James Financial set a $52.00 price target on shares of AtriCure in a research report on Tuesday. Freedom Capital upgraded AtriCure to a “strong-buy” rating in a report on Wednesday, April 1st. Canaccord Genuity Group increased their target price on AtriCure from $53.00 to $55.00 and gave the company a “buy” rating in a report on Wednesday, May 6th. Citigroup reissued a “market outperform” rating on shares of AtriCure in a research report on Tuesday. Finally, Weiss Ratings cut AtriCure from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Monday, May 4th. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, AtriCure presently has an average rating of “Moderate Buy” and a consensus target price of $49.12.

Check Out Our Latest Stock Report on AtriCure

AtriCure Company Profile

(Get Free Report)

AtriCure, Inc is a medical device company focused on the development, manufacture and marketing of innovative therapies to treat atrial fibrillation (AF) and related conditions. Founded in 2000 and headquartered in Mason, Ohio, AtriCure has established itself as a leader in surgical ablation devices designed to interrupt the errant electrical pathways that cause AF. The company’s solutions are used by cardiac surgeons and electrophysiologists to reduce the risk of stroke and improve patient outcomes in the treatment of both paroxysmal and persistent AF.

The company’s product portfolio centers on its Synergy Surgical Ablation System, which delivers controlled radiofrequency energy in a minimally invasive format, and the cryoICE Cryoablation System, which offers an alternative ablation modality using precise freezing techniques.